SCHEMBL2403213

SCHEMBL2403213

O=CNC1CC(=O)OC1=O

nearest known ligand 0.33

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CTRB1 P17538 1/20 0.33
ADH1B P00325 3/20 0.32
ADH1A P07327 3/20 0.32
ALDH1A1 P00352 1/20 0.30
TSHR P16473 1/20 0.30
ADH1C P00326 2/20 0.30
ADH7 P40394 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764272 1.00 CTRB1 (0.33) CTRB1ADH1BADH1AALDH1A1TSHR
SCHEMBL10816103 0.81 CTRB1 (0.35) CTRB1
SCHEMBL17074053 0.79 ADH1B (0.34) CTRB1ADH1BADH1ATSHRADH1C
SCHEMBL11126612 0.74 CTRB1 (0.31) CTRB1
SCHEMBL16142754 0.73
SCHEMBL9060305 0.73
SCHEMBL14867596 0.73
SCHEMBL11795515 0.69 ALOX15 (0.36)
SCHEMBL7191306 0.68 ALDH1A1 (0.30) ALDH1A1TSHR
SCHEMBL8634789 0.68 CTRB1 (0.35) CTRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709778-A1 PROCESSES FOR PREPARING A MIXTURE THAT CONTAINS A POLYOXYALKYLENE POLYOL Covestro Deutschland AG (DE) 2026-03-18 EP disclosed
WO-2024231371-A1 PROCESSES FOR PREPARING A MIXTURE THAT CONTAINS A POLYOXYALKYLENE POLYOL COVESTRO DEUTSCHLAND AG (DE) 2024-11-14 WO disclosed
EP-4461762-A1 METHOD FOR PRODUCING A MIXTURE CONTAINING A POLYOXYALKYLENE POLYOL; MIXTURE AND COMPONENTS OBTAINED FROM THE METHOD Covestro Deutschland AG (DE) 2024-11-13 EP disclosed
US-12060454-B2 Process for the continuous production of polyoxyalkylene polyols COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2024-08-13 US disclosed
EP-4114881-B1 METHOD FOR PRODUCING AN ETHER ESTOL COVESTRO DEUTSCHLAND AG (DE) 2024-01-31 EP disclosed
EP-4180474-A1 METHOD FOR THE PREPARATION OF POLYETHER CARBONATE ALCOHOLS Covestro Deutschland AG (DE) 2023-05-17 EP disclosed
EP-3717537-B1 REACTION SYSTEM FOR A 1K-POLYURETHANE FOAM COVESTRO DEUTSCHLAND AG (DE) 2023-04-19 EP disclosed
US-20230086177-A1 PROCESS FOR PREPARING POLYETHER CARBONATE POLYOLS COVESTRO DEUTSCHLAND AG (DE) 2023-03-23 US disclosed
EP-3980480-B1 METHOD FOR CONTINUOUS PRODUCTION OF POLYOXYALKYLENPOLYOLS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-03-22 EP disclosed
US-20230070697-A1 PROCESS FOR PRODUCING AN ETHER ESTEROL COVESTRO DEUTSCHLAND AG (DE) 2023-03-09 US disclosed
EP-1390358-A4 AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNE MODULATORS AND ANTICANCER AGENT PHARMAGENESIS INC (US) 2004-06-16 EP disclosed
US-6730289-B2 HAIR STYLING MIXTURE COMPRISING AN ACYLATED CARBAMATE GROUP MODIFIED POLYURETHANE AND ACCEPTABLE CARRIER OR DILUENT; NO DEPOSITS ON HAIR, WATER SOLUBLE UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2004-05-04 US disclosed
EP-1390358-A1 AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNE MODULATORS AND ANTICANCER AGENT PHARMAGENESIS, INC. (US) 2004-02-25 EP disclosed
US-6569893-B2 Administering to a patient a triptolide or its derivatives, containing an amino acid or oligopeptide moiety for the treatment of cancer and autoimmune deseases, or inhibition of transplant rejection, graft versus host disease PHARMAGENESIS, INC. 2003-05-27 US disclosed
US-20020193419-A1 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents PHARMAGENESIS, INC. 2002-12-19 US disclosed
US-20020176837-A1 Cosmetic composition UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2002-11-28 US disclosed
WO-2002074759-A1 AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNE MODULATORS AND ANTICANCER AGENT PHARMAGENESIS, INC. (US) 2002-09-26 WO disclosed
WO-2002058645-A1 POLYURETHANES, COSMETIC COMPOSITIONS CONTAINING THEM AND METHOD OF PREPARATION UNILEVER PLC (GB) 2002-08-01 WO disclosed
US-6376151-B1 HYDROXYPOLYAMIDES ASAHI KASEI KABUSHIKI KAISHA (JP) 2002-04-23 US disclosed
EP-1096316-A1 POSITIVE RESIST COMPOSITION Asahi Kasei Kabushiki Kaisha (JP) 2001-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020176837-A1 Cosmetic composition POLR1C, ALKBH5, HAT1 CTRB1 2640/4885ADH1B 3167/4885ADH1A 3063/4885
US-20020193419-A1 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents CCRL2, CCR1, XPNPEP1 CTRB1 1072/4885ADH1B 4574/4885ADH1A 4756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.